Fast-track your RNA therapy without compromising quality.
Partner with specialist RNA CDMO Exothera and access the benefits of Ntensify™ – the world-first continuous-batch RNA production platform developed by sister company Quantoom Biosciences.
With access to leading-edge technology and an expert CDMO partner, you can accelerate the progress of your RNA therapy from the earliest stages of drug development and beyond with confidence. By standardizing and automating our process, we remove scale-up and process development steps, helping you reduce costs and achieve higher quality and yields.
By harnessing the expertise of Exothera and the power of Ntensify™, we enable you to:
From vaccines to personalized cancer medicines, our scalable platform and technical capabilities enable you to develop and manufacture high-quality nucleic acid-based therapies.
Take the first step in your continuous-batch RNA manufacturing journey and discover where Ntensify™ can take you.
Exothera is a Belgium and US-based CDMO delivering customized process development and GMP manufacturing services for viral vectors (AAV, AV, HSV, LVV, …) and mRNA or saRNA projects. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide bespoke process optimization and GMP clinical and commercial production of viral vectors and nucleic acids.